Analysts have raised their price target for Calumet from $19.25 to $20.25, citing improved margin expectations and a lower perceived discount rate, even though growth forecasts have been slightly reduced.
What's in the News
- Calumet received an update from the EPA confirming that all of its small refinery exemption petitions filed from 2019 through 2024 have been granted either full or partial exemptions (Key Developments).
- The decision by the EPA will significantly lower Calumet's RIN balance sheet accrued liability from 396 million RINs to 89 million RINs (Key Developments).
- Of the remaining 89 million RINs liability, 57 million are attributed to the 2022 and 2023 vintages, and 32 million to 2024 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from $19.25 to $20.25, reflecting a modest improvement in perceived value.
- Discount Rate has decreased significantly from 9.15% to 8.23%, which indicates lower perceived investment risk.
- Revenue Growth forecast has declined slightly, moving from 8.00% to 7.56%.
- Net Profit Margin estimate has risen modestly, up from 0.79% to 0.80%.
- Future P/E ratio has increased from 55.32x to 56.74x, suggesting higher expected future earnings valuation.
Have other thoughts on Calumet?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.